SAN DIEGO, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)VACCINE RESEARCH INSTITUTE OF SAN DIEGO, founded in 2001, is a small nonprofit in the Medical Research sector that reported $665K in total revenue in fiscal year 2024. Revenue surged 25% from the prior year, signaling strong growth momentum. Expenses of $625K left a modest 6% surplus.
OUR MISSION IS SCIENTIFIC RESEARCH FOCUSING ON DEVELOPMENT OF PREVENTATIVE AND THERAPEUTIC TREATMENTS FOR BOTH INFECTIOUS (MAALARIA, HEPATITIS B AND C, AND INFLUENZA) AND NON-INFECTIOUS DISEASES (CANCER AND CARDIOVASCULAR DISEASE).
Our mission is scientific research focusing on development of preventative and therapeutic treatments for both infectious (malaria, hepatitis B and C, and influenza) and non-infectious diseases...
Our mission is scientific research focusing on development of preventative and therapeutic treatments for both infectious (malaria, hepatitis B and C, and influenza) and non-infectious diseases (cancer and cardiovascular disease).These studies involve the development of new cancer therapeutics as well as prophylactic and therapeutic vaccines. The goal is to bring to fruition treatments for diseases which have plagued millions of people worldwide and to share these results with the scientific community and the public.To accomplish these goals the VRISD has recruited and will continue to recruit researchers with expertise in Molecular Biology, Pharmacogenomics, Peptide Chemistry, Bioinformatics, Oncology and Immunology. These areas of expertise will allow us to gain an understanding of the host-pathogen and host-tumor interactions as they relate to effective therapeutic design. VRISD scientists are working together for the purpose of eradicating diseases that have eluded researchers and physicians in the past, with the ultimate goal of providing better health for all people worldwide.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $664,888 | $531,611 | +0.3% |
| Expenses | $625,296 | $568,268 | +0.1% |
| Net Income | $39,592 | $-36,657 | -2.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| CORY PETERS | SR SCIENTIST | 40.00 |
|
$98,700 | $0 | $98,700 |
| DAVID WHITACRE | Sec/Treas | 20.00 |
Officer
|
$74,400 | $3,850 | $78,250 |
| DAVID R MILICH | President | 20.00 |
Officer
|
$56,018 | $2,801 | $58,819 |
| JOYCE JONES | CEO | 5.00 |
Officer
|
$12,000 | $0 | $12,000 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $664,888 | $625,296 | $32,142 | $39,592 |
| 2024 | $531,611 | $568,268 | $28,454 | $-36,657 |
| 2019 | $450,814 | $398,797 | $103,780 | $52,017 |
| 2018 | $767,443 | $813,436 | $274,396 | $-45,993 |
Compare VACCINE RESEARCH INSTITUTE OF SAN DIEGO with other nonprofits in California and across the country.